articleThe Lancet OncologySep 3, 2012Closed access

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

University of Colorado Denver · Seoul National University · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,275
total citations
FWCI
122.95
Percentile
100%
References
49
Citations per year

Authors

24

Topics & keywords

Keywords
  • Crizotinib
  • Medicine
  • Tolerability
  • Internal medicine
  • Lung cancer
  • Oncology
  • Population
  • Phases of clinical research
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding